JP2017502023A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502023A5
JP2017502023A5 JP2016540993A JP2016540993A JP2017502023A5 JP 2017502023 A5 JP2017502023 A5 JP 2017502023A5 JP 2016540993 A JP2016540993 A JP 2016540993A JP 2016540993 A JP2016540993 A JP 2016540993A JP 2017502023 A5 JP2017502023 A5 JP 2017502023A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
macular degeneration
age
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502023A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/049938 external-priority patent/WO2015099838A2/en
Publication of JP2017502023A publication Critical patent/JP2017502023A/ja
Publication of JP2017502023A5 publication Critical patent/JP2017502023A5/ja
Pending legal-status Critical Current

Links

JP2016540993A 2013-12-24 2014-08-06 眼疾患を治療する組成物および方法 Pending JP2017502023A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920541P 2013-12-24 2013-12-24
US61/920,541 2013-12-24
PCT/US2014/049938 WO2015099838A2 (en) 2013-12-24 2014-08-06 Compositions and methods of treating ocular diseases

Publications (2)

Publication Number Publication Date
JP2017502023A JP2017502023A (ja) 2017-01-19
JP2017502023A5 true JP2017502023A5 (enExample) 2017-09-14

Family

ID=53479755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540993A Pending JP2017502023A (ja) 2013-12-24 2014-08-06 眼疾患を治療する組成物および方法

Country Status (6)

Country Link
US (2) US10183989B2 (enExample)
EP (1) EP3086809A4 (enExample)
JP (1) JP2017502023A (enExample)
AU (1) AU2014370404A1 (enExample)
CA (1) CA2934462A1 (enExample)
WO (1) WO2015099838A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CN116514976A (zh) 2016-03-04 2023-08-01 Jn生物科学有限责任公司 针对tigit的抗体
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California CANCER TREATMENT COMBINATIONS
KR20230041834A (ko) * 2016-08-16 2023-03-24 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
WO2019033081A1 (en) * 2017-08-11 2019-02-14 Massachusetts Eye And Ear Infirmary INHIBITION OF THE SUPPLEMENTARY ALTERNA PATHWAY FOR THE TREATMENT OF RETINAL ISCHEMIC LESION AND GLAUCOMA
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
KR20200138290A (ko) 2018-04-03 2020-12-09 엔지엠 바이오파마슈티컬스, 아이엔씨. C3-결합제 및 이의 사용 방법
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN109999015A (zh) * 2019-04-24 2019-07-12 江苏省中医药研究院 紫草素在制备预防或治疗房颤药物中的用途
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
CN116710135A (zh) * 2020-10-07 2023-09-05 6线生物技术公司 用于治疗眼部疾病的方法和试剂
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040406A2 (en) * 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
EP1931379B1 (en) * 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
EP2596807B1 (en) 2006-03-08 2015-12-16 Archemix LLC Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US20100015139A1 (en) * 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
KR101572700B1 (ko) * 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
CN103003302B (zh) 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
CN104220453B (zh) 2012-04-03 2018-03-09 诺沃姆德治疗公司 人源化的嵌合抗因子c3抗体及其用途
JP6244350B2 (ja) 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド. ヒト化およびキメラ抗因子Bb抗体、ならびにその使用

Similar Documents

Publication Publication Date Title
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
NZ706377A (en) Il-6 antagonists and uses thereof
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
WO2014152006A3 (en) Anti-hepcidin antibodies and uses thereof
AR105267A1 (es) Anticuerpos de unión a tau
WO2014186622A3 (en) Methods of treatment for guillain-barre syndrome
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses
WO2018165062A8 (en) Anti-c5 antibodies and uses thereof
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
PH12016502608A1 (en) Humanized anti-tau antibodies
HK1208499A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2014062659A3 (en) Methods of treating ocular diseases
WO2017079443A8 (en) Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody